Home / Transcripts / Arvinas, Inc. (ARVN) · February 24, 2026

Arvinas, Inc. (ARVN) Earnings Call Transcript

February 24, 2026

NASDAQ US Health Care Pharmaceuticals earnings 73 min

Earnings Call Speaker Segments

Jeff Boyle executive
#1

Hello, everybody, and thanks for being with us today. We put out a press release this morning containing our financial results for the fourth quarter and for the full year 2025, and you can find it in the Investor and Media section on arvinas.com. On the line with us this morning are Randy Teel, who serves as our President and CEO; Noah Berkowitz, our Chief Medical Officer; Angela Cacace, our Chief Scientific Officer; and Andrew Saik, our Chief Financial Officer. Prior to getting started, please be aware that forward-looking statements are part of what we'll discuss today, and those carry risks, uncertainties and assumptions; details about these risks and uncertainties appear in the press release issued today as well as in the company's recent filing with the Securities and Exchange Commission, and I encourage you to review them. What we actually achieve could differ materially from the contents of today's call. A replay of this call, along with the press release from today and a refreshed corporate deck, will be posted in the Investor and Media section of our website. With that, I'll hand things over to Randy Teel. Randy?

Randy Teel executive
#2

Thanks, Jeff, and I appreciate everyone being here today. Leading such a gifted and dedicated team is both an honor and a privilege as Arvinas moves into a stretch where we expect numerous milestones that will drive value for the company; alongside the team, we possess a technology that has been validated in the clinic, a promising pipeline and a robust balance sheet, which lets us keep working toward a significant impact for patients, their families and our shareholders. Across our pipeline, 2025 brought substantial progress and marked a transformative year for the company; beyond filing our initial new drug application, which sets up what could be the first FDA approval ever for a PROTAC degrader, we reshaped our strategy so we can maximize the opportunities ahead within each of our core focus areas. With 4 clinical trials currently running in oncology and neurology, among them our recently launched first-in-human study of ARV-027, our polyQ-AR degrader, we think we can potentially deliver genuinely differentiated therapies to millions of patients who are underserved. Arvinas is now entering a pivotal period. As we have been signaling over the past 6 months, 2026 is going to be shaped by several data readouts and clinical advances; in our view, these milestones will confirm our approach of developing only treatments that stand clearly apart from other options. Before I hand the call to the team to review recent achievements and our forward-looking plans in greater detail, I'll go over clinical data expectations for the year and offer a few remarks on corporate strategy. Starting with ARV-102, our LRRK2 degrader, I'm happy to share today that data from our Phase I clinical trial involving patients with Parkinson's disease has been accepted for an oral presentation at the Alzheimer's Disease and Parkinson's Disease Conference in March. We'll evaluate how well ARV-102 degrades LRRK2 in the CSF and examine its effect on key pathway biomarkers. Instead of intermittently inhibiting LRRK2's kinase activity, ARV-102 degrades the whole LRRK2 protein, which matters a great deal when considering its potentially differentiated profile. Now to ARV-806. Our KRAS G12D PROTAC powerfully and selectively removes both the ON and OFF forms of the protein. Given enrollment that moved faster than we anticipated in this trial, we now expect our first data disclosure for the program by the middle of 2026, and data from that trial has already been submitted for presentation at a medical congress in the coming months. This should offer an important look at why we think ARV-806 could be a clearly differentiated treatment. So keep watching for more on our disclosure plans. Moving on, ARV-393, our PROTAC BCL6 degrader, continues to advance well in our Phase I dose escalation trial, and we plan to share data from this trial in the second half of 2026. As we announced on our last earnings call, responses have already appeared in early cohorts among patients with both B- and T-cell lymphomas, even at exposures lower than those predicted to be efficacious. We likewise saw strong degradation of BCL6, and 393's safety data backs ongoing dose escalation. Regarding vepdegestrant, as everyone knows, we're collaborating with Pfizer to choose a third party for commercializing it and possibly advancing its development further. Our aim is still to ensure that, should approval come, vepdeg is ready to launch and offered as a potentially best-in-class therapeutic choice for patients facing ER-positive-HER2-negative advanced breast cancer in the second-line ESR1 mutant setting. Talks so far with prospective partners have gone well, and we're striving to finalize an agreement ahead of the June 5 PDUFA date. Lastly, before handing things to the team, I want to offer two remarks about corporate strategy. First, a year ago, we chose to redirect our resources toward our Phase I clinical programs, of which we currently have 4. Although we think vepdeg could become a best-in-class therapy for patients, we believe the optimal path for Arvinas to build shareholder value lies in concentrating on ARV-102, ARV-806, ARV-393 and now ARV-027. Second, we understand the standard is elevated across all our programs. We refuse to accept merely matching others, and we hope patients won't face a tradeoff among efficacy, safety and tolerability. We're committed to developing only differentiated treatments and will be extremely disciplined about pushing programs ahead. We believe our pipeline is generating potentially transformative treatments for patients, and we're eager to share what we expect will be compelling data for every one of these programs as milestones arrive down the road; with that, I'll pass the call to Noah. Noah?

Noah Berkowitz executive
#3

Appreciate that, Randy, and hello to all of you this morning. I'd like to start off by discussing ARV-102, which is our LRRK2 degrader. To give some context here, ARV-102. Angela?

Angela Cacace executive
#4

Thank you, Noah, and hello everybody on this call. To begin, I'd like to provide a few more specifics regarding ARV-027, the PROTAC degrader we've created to go after the polyglutamine-expanded androgen receptor, or polyQ-AR, found in skeletal muscle. Building AR degraders is an area where we possess considerable know-how. An AR degrader served as our initial clinical candidate. And luxdegalutamide, a compound we licensed out to Novartis during 2024, is moving ahead across several Phase II studies involving hormone-sensitive as well as castrate-resistant prostate cancer. In spinal and bulbar muscular atrophy, or SBMA — which people also call Kennedy's disease — polyQ-AR represents the underlying cause. SBMA is an uncommon neuromuscular condition driven by genetics, and because nothing has been approved to treat it, the unmet need is substantial. As some background: SBMA follows an X-linked pattern and arises from a CAG expansion within the AR gene, which leads to polyQ-AR building up; this harmful buildup compromises contractility, producing atrophy and eventually weakness along with a loss of endurance in the muscle. When creating a disease-modifying treatment for SBMA, the aim is to lower polyQ-AR within muscle; our view is that ARV-027 possesses the right profile to potentially become the very first therapy for SBMA patients that addresses the protein at the disease's genetic origin. ARV-027 is a PROTAC that triggers degradation of polyQ-AR in skeletal muscle. Last year, during October, at the World Muscle Society Conference, we shared the initial preclinical findings on ARV-027, and later this week we'll present data once more at the Kennedy's Disease Association Conference. According to these results, oral ARV-027 produced degradation of muscle polyQ-AR, leading to obvious functional gains and longer survival in a rapidly progressing mouse model of SBMA. We've lately launched our Phase I study of ARV-027 in healthy volunteers, and we're thrilled to be advancing ARV-027 for the thousands of people living with spinal and bulbar muscular atrophy, an illness lacking any approved disease-modifying therapies. To complete the set of programs we anticipate bringing into the clinic during this year, there's ARV-6723, our initial immuno-oncology-focused PROTAC degrader aimed at solid tumors, which targets HPK1. Within the immune system, HPK1 functions as a central intracellular brake, stifling T-cell receptor signaling and broadly blunting antitumor responses of both the innate and adaptive kind. In addition to its kinase activity, HPK1 plays a scaffolding role that further strengthens immune suppression, which makes it an appealing kinase to degrade instead of inhibit. In preclinical work, ARV-6723 has produced deep and lasting HPK1 degradation, removing both the kinase and scaffolding functions — something that kinase inhibition by itself cannot accomplish. Used as a single agent, ARV-6723 showed meaningful and durable control of tumor growth across numerous syngeneic models, covering tumors that are both high- and low-immunogenic, and it beat an investigational HPK1 inhibitor as well as anti-PD-1 therapy in multiple settings. It likewise showed potent activity when combined with anti-PD-1. From a mechanistic standpoint, degrading HPK1 generates a distinctive pro-inflammatory tumor microenvironment featuring more activated T-cells, NK cells and monocytes. Furthermore, ARV-6723 was observed to lower immunosuppressive neutrophils while triggering wider pro-inflammatory pathway activation than inhibition by itself. During the AACR Immuno-Oncology Conference last week, we shared preclinical results showing ARV-6723 has strong single-agent activity and beats the clinical HPK1 inhibitor in efficacy trials using several mouse models that reflect hot and cold immunological conditions, plus we showed it works in multiple models of resistance to anti-PD-1. Taken together, this information establishes ARV-6723 as a potentially differentiated oral immuno-oncology strategy intended to generate deeper and longer-lasting antitumor responses. There's potential for ARV-6723 to tackle major unmet need in various settings where immunotherapy drugs available today haven't worked. Subject to regulatory feedback, we intend to launch first-in-human trials for ARV-6723 in the latter part of this year. And given what we've seen preclinically, we think ARV-6723 might transform the treatment paradigm within the immuno-oncology landscape. Lastly, our oral pan-KRAS PROTAC program is advancing well — a preclinical effort that pairs with our clinical KRAS G12D degrader. What sets our pan-KRAS PROTAC apart from every inhibitor is that this novel oral degrader is built to eliminate KRAS. In preclinical work, we've shown wide degradation across KRAS alterations, such as wild-type amplified KRAS, with selectivity above RAS isoforms and activity in both ON and OFF states. By degrading and clearing the oncoprotein relative to pan-RAS inhibitors, we've seen stronger anti-proliferative and apoptotic effects, greater tumor growth inhibition, and boosted activity when paired with anti-PD-1 therapy, offering preclinical support for a differentiated profile. We'll share preclinical data at the AACR Special Conference on RAS in March comparing our PROTAC pan-KRAS degrader against pan-RAS inhibitors, and we'll also present data featuring efficacy in a KRAS syngeneic model along with related immune microenvironment changes at a scientific congress during the first half of this year. With that, I'll hand the call to Andrew for our quarterly financial review. Andrew?

Andrew Saik executive
#5

Angela, thank you — and good morning to all of you. I'm glad to walk through our financial results for Q4 along with the full year that closed on December 31, 2025. Just a note before I begin: complete figures for the fourth quarter and year-end, which include a reconciliation between GAAP and non-GAAP measures, can be found in the press release that went out earlier today. With the data readouts we expect later in the year ahead of us, our finances remain solid enough to keep our guidance intact — cash that lasts into the second half of 2028. When the fourth quarter closed, our balance sheet showed a little more than $685 million across cash, cash equivalents and marketable securities, versus a bit over $1 billion when 2024 came to an end. We're confident that this healthy balance sheet lets us move our programs forward toward significant data events, and those will guide key portfolio choices over the months and years ahead. Now to the Q4 and full-year 2025 financial highlights. Revenue for the quarter came in at $9.5 million, whereas the comparable period of 2024 brought in $59.2 million. That drop stemmed mainly from a $40.3 million decline in revenue tied to the Novartis license agreement. For the full year, we booked $262.6 million in revenue, against $263.4 million in fiscal year '24. General and administrative expenses reached $23 million in Q4, versus $34.1 million during the matching period in 2024. That $11.1 million reduction came largely from a $4.4 million fall in personnel and infrastructure-related costs, plus a $3.1 million decrease in costs tied to building out our commercial operations. For the year, G&A expenses totaled $95.9 million, compared with $165.4 million a year earlier. On a non-GAAP basis, fourth quarter G&A expenses were $15.3 million in 2025, down from $23.7 million in 2024. Research and development expenses came to $61.1 million in Q4, against $83.3 million in the same quarter of 2024. That $22.2 million decrease was driven mostly by a $14.1 million drop in compensation and related personnel expenses, along with a $7.6 million reduction in external expenses. For the year ended December 31, 2025, R&D expenses were $285.2 million, compared with $348.2 million a year earlier. Fourth quarter non-GAAP R&D expenses were $56.5 million in 2025, versus $70.4 million in 2024. Total non-GAAP expenses for Q4 and the full year were $71.8 million and $323.4 million, respectively. Our lower spending in Q4 reflects directly the cost-cutting work we did in 2025, and we'll keep hunting for efficiencies in how we operate this year. As we shared previously, in September our Board gave the go-ahead to repurchase as much as $100 million of our outstanding common stock. By year-end, we had repurchased roughly 10 million shares, paying an average of $9.09 per share, for a total of $91.9 million once commissions and excise tax are included. That program is suspended at this point, and we don't intend to buy back any additional shares. You can find the specifics of our buyback initiative in the 10-K we're releasing later today. As I noted, we're keeping our guidance for cash runway unchanged through the latter portion of 2028, which gives us the ability to hit key data readouts and to keep directing funding toward efforts we consider genuinely differentiated and that will deliver meaningful advantages to patients. I'll hand things back over to Randy now for his closing thoughts. Randy?

Randy Teel executive
#6

Appreciate that, Andrew. I'll give a quick recap, then we can move into Q&A. Looking ahead across 2026, we expect to report additional clinical findings from the Phase I studies of ARV-102, 806, and 393; our polyQ-AR degrader, which has only recently begun testing in humans, should be joined in the clinic later in the year by our HPK1 degrader, and we anticipate that significant new studies will launch for ARV-102 as well as 393. My view is that Arvinas is now stepping into a stretch of real execution and value creation. It's rare for a Phase I-stage company to hold such a robust pipeline and the funding needed to hit key milestones, and rarer still to have a platform with positive Phase III clinical trial results already disclosed. That's precisely why I feel such excitement about the chances ahead of us to deliver a real difference for patients and shareholders. On that note, I'll pass things over to Jeff to kick off Q&A. Jeff?

Jeff Boyle executive
#7

Appreciate that, Randy. Just a note that if you aren't able to get into the queue, we're happy to handle your questions outside of this call at any time; that said, at this point I'll have the operator unlock the lines so we can begin Q&A. Operator?

Randy Teel executive
#8

Operator, Randy here—actually, I'm hopping back on because we've got a slight shift in the plan. Before we hand things over to the operator again and start the Q&A, there's one additional part we need to get through. Particularly given the storm that arrived over the last 2 days, we recorded the prepared remarks ahead of time so that we wouldn't run into any technical problems. Clearly, we did, and a number of you picked up on the fact that Noah's portion was largely passed over. So now we're going to have Noah deliver his section live, and right after that we'll go directly into Q&A. Noah?

Noah Berkowitz executive
#9

Appreciate that, Randy. All right, so let's move on to a few of our clinical stage assets. To give some context, ARV-102 is an oral PROTAC LRRK2 degrader that was deliberately engineered to penetrate the blood-brain barrier and to selectively degrade leucine-rich repeat kinase 2, or LRRK2. LRRK2 is a multi-domain protein possessing three key functions: kinase, GTPase, and scaffolding activities. Taken together, the activities of LRRK2 regulate endolysosomal trafficking, and when that activity becomes elevated, the lysosome stops functioning properly. This produces obstructions in the clearance of aggregated pathological proteins that under normal circumstances would be broken down via a properly functioning lysosomal pathway. Our belief is that degrading LRRK2 could potentially restore endolysosomal homeostasis and deliver therapeutic benefit in disorders defined by lysosomal dysfunction. Progressive Supranuclear Palsy, or PSP, and Parkinson's disease are two such diseases. A number of competitors are going after LRRK2 as a target in these diseases. What sets our PROTAC approach apart is that we lower LRRK2 protein, whereas competitors merely inhibit the kinase function of LRRK2. Through degradation of the whole LRRK2 protein complex, we disrupt the key functions thought to be tied to neuro-inflammation and lysosomal dysfunction. That's a significant consideration when you think about a differentiated profile, since ARV-102 carries the potential for deeper and more durable therapeutic benefit relative to inhibitors. Our confidence in this program is reinforced by data we've produced from our Phase I clinical trials in healthy volunteers in Parkinson's disease. As we've previously disclosed, ARV-102 has been well tolerated and shown dose-dependent CSF exposure in both trials, which points to excellent brain penetration. We also reported that ARV-102 lowered LRRK2 in the CSF by more than 50% and reduced downstream proteins driven by LRRK2 variants that are elevated in the CSF of patients with Parkinson's disease and tied to lysosomal stress. Two of these proteins, GPNMB and CD68, show clear and disease-relevant pathway engagement in the central nervous system, even in healthy volunteers, in whom elevation would not have been expected. All in all, these data offer further evidence that total protein degradation of LRRK2 kinase may deliver a best-in-class impact on the underlying disease relative to inhibition. As Randy noted, we were accepted for an oral presentation at AD/PD, where we'll present pathway biomarker results in patients with Parkinson's disease; we look forward to updating you on those data. Let's now shift to the development plan for ARV-102. As we've shared before, there's strong evidence that endolysosomal trafficking driven by increased LRRK2 is linked to a clinically meaningful progression, often within 1 year, of PSP, a progressively debilitating neurodegenerative disease that is typically fatal within 5 to 7 years of diagnosis. We plan to launch a Phase Ib trial in PSP in the first half of this year, with the possibility of starting a registrational trial in late 2026, subject to health authority feedback. If it succeeds, ARV-102 could potentially become the first and only disease-modifying treatment for this rare, life-threatening neurological disorder, which affects approximately 25,000 people every year in the U.S.; we expect to offer additional updates on our clinical development plans in the months ahead. Now let's turn to ARV-806, our degrader of KRAS G12D. I should mention that in our Phase I study, we finished dose escalation for once-weekly dosing far sooner than we had anticipated. We think this speaks to significant enthusiasm among clinical investigators and considerable demand for therapies that effectively target KRAS. The goal for ARV-806 is elimination of KRAS G12D. This mutation is a recognized oncogenic driver tied to unfavorable outcomes and resistance to conventional therapies in several major tumor categories, such as pancreatic, colorectal, and non-small cell lung cancers. Critically, no targeted treatments have received approval for tumors carrying KRAS G12D mutations. As a reminder, during our previous call, we discussed preclinical findings presented at the Triple Meeting in October that demonstrated clear differentiation of ARV-806 from both KRAS inhibitors and degraders presently in the clinic. According to those preclinical results, ARV-806 was over 25-fold more potent at lowering cancer cell proliferation than clinical stage KRAS G12D inhibitors and the top clinical stage G12D degrader. Those data further revealed durable degradation exceeding 90% for 70 days — pardon me, for 7 days following a single dose, with efficacy responses seen across pancreatic, colorectal, and lung cancer models; we expect to share initial Phase I clinical data within the next few months. The bar for differentiation is extremely high, and we think ARV-806 could potentially transform this field by clearing that bar. Let's move on to ARV-393, an oral investigational novel BCL6 degrader that has the potential to become a chemo-free standard of care for non-Hodgkin's lymphoma indications. BCL6 undergoes rapid resynthesis and is recognized as hard to target with inhibitors. The iterative event-driven mechanism of action of ARV-393 counteracts BCL6's fast resynthesis rate, producing potent, sustained degradation of the protein. As we announced during our Q3 earnings call, responses have already been seen in both B- and T-cell lymphomas among the early cohorts of our ongoing Phase I monotherapy trial, even at exposures lower than those predicted to be efficacious. We also saw evidence of robust BCL6 degradation, and the safety profile of ARV-393 supports continued dose escalation. In preclinical data presented last year, ARV-393 demonstrated broad synergistic antitumor activity when combined with standard of care biologics and investigational small molecule inhibitors. In December, we presented compelling preclinical data supporting ARV-393 in combination with glofitamab, a CD20-directed bispecific antibody, as a chemotherapy-free combination approach in diffuse large B-cell lymphoma or DLBCL. Those data showed tumor growth inhibition of 91% with ARV-393 plus glofitamab dosed sequentially, versus 36% for glofitamab alone. In addition, RNA sequencing and biomarker analyses indicated that ARV-393 boosts CD20 expression and genes that promote interferon signaling and antigen presentation, while also down-regulating proliferation-associated gene sets. Taken together, these preclinical data point to mechanistic synergies between BCL6 degradation with ARV-393 and T-cell engagement. We believe these results offer hope for DLBCL patients who have minimal treatment options remaining once standard of care therapies fail. Thanks to the promising results we've seen before human testing, we remain on schedule to launch our Phase I study combining glofitamab during the opening six months of this year. So at this point, I'll hand things over to the operator so we can begin Q&A.

Jon Miller analyst
#10

Congratulations on the strides being made throughout numerous intriguing-looking programs. Something that strikes me right away from a few of your prepared comments is the claim that development will only proceed for programs where differentiated activity can be observed. As you know well, several of these are in crowded spaces; therefore my question is about the pipeline overall — when will you obtain the decisive data that tells you whether a program is differentiated? Clearly this varies by program; even so, could you walk us through the pipeline and share what you regard as the crucial experiment revealing whether something is genuinely differentiated?

Randy Teel executive
#11

Yes, John, many thanks for asking. As we kick off the Q&A, once more I want to apologize to everyone joining the call for that mix-up. I hope it came across clearly when we needed to redo Noah's portion. John, we could probably fill most of the day addressing that question, correct? So as you noted, every program will differ. And of course, when we consider a strategy requiring clear differentiation from competitors — which strikes me as fairly sensible — that doesn't mean initial data from a very early Phase I study must already surpass a rival possessing expansion data, Phase III data, and so forth. So shortly I'll hand things to Noah, who can perhaps go program by program through certain specifics we anticipate this year, likely the best area to concentrate on. Looking broadly, though, maybe I'll point out a few items: regarding LRRK2, for ARV-102, our LRRK2 degrader, inhibitors represent the competition there. Demonstrating that degradation produces an outcome distinct from inhibition will matter greatly, for a target that drugs the industry has developed have never proven to modify disease overall. That's therefore a major risk. With 806 for KRAS G12D, the target enjoys far more validation, yet the competitive landscape is considerably more crowded given other programs that got there before it; for BCL6, in the same way, the target is fairly new, though competitors exist who have partially cleared the path, demonstrating the target has become somewhat validated now; and perhaps we'll set 027 aside at this point. Still, I believe for all of those, Phase I data will draw some attention, and going forward we'll need to make comparisons as time passes. Noah, is there anything further you'd like to mention, perhaps concerning certain near-term data updates?

Noah Berkowitz executive
#12

Absolutely, Randy, and I appreciate that. To illustrate, let's begin with ARV-102. In that instance, we've conveyed quite a strong level of confidence. We've stated that a PSP trial is kicking off this year, subject to regulatory clearance. It's even possible we could advance toward a registration-quality study prior to the close of this year. So we feel we've already demonstrated our edge. We understand there are certain attributes of an LRRK2 inhibitor that LRRK2 degraders are capable of surpassing. In healthy volunteers, we've already shown we can hit over 50% LRRK2 degradation in the brain. That figure has been our objective. We've been stating that plainly, because broadly speaking — to put it simply — Parkinson's patients exhibit two to three times the amount of LRRK2 protein expression in the brain relative to age-matched controls. So we aimed to reach something inhibitors simply cannot achieve. That's the reason our confidence is high there, along with pathway data, with more arriving at AD/PD in April. Turning now to 806. That area is intensely competitive; we're aware of numerous other G12D-targeting agents ahead of us, primarily inhibitors and, I'd say, a single degrader. Yet honestly, this actually works in our favor, since we can see where the bar sits. We recognize — and I'll put this broadly, not pinning down the exact target, since this isn't — because the science isn't precise — but we recognize we need to outperform roughly 35% response rates in this area in order to stand apart. So we'll need to produce data giving us assurance that we're superior. As the year progresses, we'll indicate precisely what degree of confidence we hold and what — as we're able to share data publicly. Still, it's evident from the many drugs currently in the clinic that we must beat the vast majority of them, which lands us in that range. Then regarding 393, we're essentially in the lead position at present. One competitor has released data, and we do observe activity from their drug; however, it's genuinely early days — we're talking months, or perhaps — I'd rather not specify a timeframe for how far behind we might be. It's difficult to determine. Still, we're essentially at the forefront of this today. So we'll examine whatever data our competitor releases; we'll examine the data we produce. We'll make that public. And we're confident that across all three of these drugs, data will emerge this year showing their differentiation, which we ought to have shared with our investors as the year unfolds.

Edward Tenthoff analyst
#13

Randy, my congratulations to you and the entire team — the energy you all bring is something I genuinely value. Having this early-stage program move ahead with so many truly distinctive shots on goal is genuinely thrilling. I'd like to return to what Noah mentioned regarding 102. What exactly ought we to anticipate from those data at AD/PD? And might there be a stepwise PSP update before the registrational trial begins? The pace at which you're advancing here is something I love, yet I'd like to grasp what the bar is for progressing into registrational studies?

Randy Teel executive
#14

Perhaps I'll handle the latter portion of that, then hand it back regarding what to expect for AD/PD. Ted, my answer to that, I believe, is no. The explanation is simply the schedule we set out in the prepared remarks a moment ago: we expect to kick off a Phase Ib in PSP earlier. Then, as we've stated, provided everything breaks our way and subject to — additional data from AD/PD plus regulatory clearance, our hope would be to launch a registrational trial before the year ends; so the data falling in that window between beginning the PSP trial earlier in the year and reaching a second one afterward, I believe, would rule that out. Still, we believe the data we'll present at AD/PD, which come from Parkinson's patients, will hold relevance for advancing in either PD or PSP. Noah, over to you for the AD/PD perspective.

Noah Berkowitz executive
#15

Alright, so obviously we aren't able to give out results ahead of time, though I suppose I can provide some context. Several months back, we disclosed information from a study that kicked off last year and wrapped up with biomarker findings a number of months ago involving healthy volunteers. What we're going to do now is present findings from the Parkinson's disease patient group. The kinds of things a sharp scientist would want to know are: within Parkinson's disease, does this drug keep showing the same safety profile that healthy volunteers had, given that these patients are older — healthy volunteers had a median age of 25 years, while Parkinson's patients are considerably older. At baseline, LRRK2 is far more elevated in the CSF. So what appeared at low levels before is now being seen at higher levels, since you've got to push past an even greater amount of LRRK2 in the brain — and clearly those deeper regions of the brain, which the CSF levels reflect. And then there's the biomarker piece, correct? The biomarkers we're observing in healthy volunteers — is that a one-off result that can't be reproduced? Or does the trend persist, or even grow stronger, when you examine Parkinson's disease patients? That's the sort of set of questions I would focus on, and our hope is that we can provide answers to them at the meeting.

Edward Tenthoff analyst
#16

Excellent. That’s quite useful, and I’m eager to see the remaining figures and the progress reports coming later in the year.

Tyler Van Buren analyst
#17

This is Francis, filling in for Tyler. One brief item from our side. Could you say more about the pan-KRAS presentation at AACR, what results we ought to anticipate, and which competitors you’re comparing against?

Randy Teel executive
#18

Certainly. In a moment, I may hand it over to Angela to discuss that a little; and as you mention, we have a pan-KRAS program that, as we’ve said, is advancing in preclinical work following the KRAS G12D degrader, for which we’ll have data at some point this year. But Angela, could you add more about the AACR data for pan-RAS?

Angela Cacace executive
#19

Absolutely, and I appreciate the question. What we're going to be presenting is information that puts us side by side with the inhibitors. In the pan-KRAS effort, the objective is naturally to eliminate the oncoprotein, which is how we set ourselves apart from both the ON and the OFF inhibitors — the distinction being that we take the inhibitor away. The very first thing you notice — this is a regulatory phenomenon — when someone receives an inhibitor is that KRAS gets compensatorily up-regulated. That's what shows up with the ON inhibitors. So we're going to present data on KRAS amplification. We'll be showing how we stack up against the KRAS(ON) inhibitor under those conditions. Beyond that, we'll present some of the mutant data too, regarding the activity we observe — the antitumor activity — so you should look for that as well. Hopefully that answers it. In addition, we'll present data from a syngeneic model where the immune system is intact. That matters, I believe, when you think about pan-RAS inhibitors and about our pan-KRAS molecule, which is selective for KRAS rather than pan-RAS — meaning we don't touch N and HRAS, which influence T cell activity.

Manoj Eradath analyst
#20

Manoj here, filling in for Akash. I've got just one question about ARV-393. What have you observed over the year regarding plasma exposure behavior when ARV-393 is given alongside glofitamab? Would you anticipate that either 393 or glofitamab might require particular dose adjustments when the combination is used in the clinic? And then one more. Following the recent Roche vepdegestrant data, are you seeing greater interest in vepdegestrant, particularly in earlier lines?

Randy Teel executive
#21

Let me try putting that differently. On the first question about 393, I believe it was — broadly speaking, it was whether we foresee any need for dose modification of 393 together with glofi. I might let Noah address that shortly, since we got some data on that late last year. I can take the second one. Look, we believe the Roche data from late last year confirm the idea that an ER therapy will be effective where ER is what's driving the disease, which is our long-held view. So really, no. That doesn't worry me. It definitely confirms what we expected would happen. And we're hoping that, as we work with our partners at Pfizer to find a new partner to commercialize and ideally keep developing that, it gives someone the enthusiasm to do so. So no, I don't view that as a problem; but Noah, over to you regarding 393 and whether dose modifications could be needed based on the data we've presented so far.

Noah Berkowitz executive
#22

Our expectation isn't really that dose adjustments will become necessary, though out of an abundance of caution we'll include some escalation of dose in order to assess the combo. The toxicities don't overlap — meaning the main toxicity from glofitamab will be things such as CRS, and there could also be a degree of cumulative hematopoietic toxicity among patients from glofi. We, conversely, aren't truly observing toxicity in those categories at all. So we'll move it forward cautiously, yet we don't expect any dose modifications.

Yigal Nochomovitz analyst
#23

Caroline here, filling in for Yigal. So, going deeper into LRRK2 and the biomarker data that'll be shared at AD/PD, could you explain how that data backs up the therapeutic hypothesis for PSP? And on a related note, what percentage of PSP patients show elevated LRRK2? Also, are the same biomarker pathways involved as they are in Parkinson's?

Randy Teel executive
#24

Yes. That one I'll hand off pretty fast to Angela. We've made a few remarks about the biomarkers, but Angela, please go ahead and dig in.

Angela Cacace executive
#25

Okay, so with PSP, a few papers have come out lately indicating that the same pathways are upregulated. In progressive supranuclear palsy, you consistently observe heightened engagement of the endolysosomal pathway, along with elevated LRRK2 among those patients. Therefore, we anticipate seeing efficacy in that group. When you take that group and break it down to focus on those with increased LRRK2 specifically, what you find is faster progression that is clinically meaningful. Looking only at the subset with elevated levels, you observe an acceleration of 1 year, and it is clinically meaningful — roughly 20 to 30 points on the rating scale. Ed Jabbari and his colleagues at University College London demonstrated this. Those findings suggest that within this genetically defined group, that holds true. Whenever you observe heightened expression, for a PROTAC, that is exactly where you want to target. So PSP is somewhere we can demonstrate a concept within 1 year. That encourages us, and we stay strongly committed to this therapeutic hypothesis in PSP.

Derek Archila analyst
#26

Understood. Aside from that, do we have any news regarding the choice of a third party for vepdeg?

Randy Teel executive
#27

Nothing beyond what was included in this morning's remarks. That remains on schedule. We're feeling positive about the process we're working through together with Pfizer, but everything is proceeding as planned, and our expectation is to have a partner secured before the PDUFA date at the start of June.

Analyst analyst
#28

Jacob here, filling in for Derek. We have just a single question regarding LRRK2. What's the right way to approach safety when the AD/PD data come out? I realize this trial is fairly brief, but with the lung biology tied to LRRK2, is there anything you'd expect to show up, or anything you'll be watching for at this point in time that would boost your confidence going into a study of longer duration?

Randy Teel executive
#29

Yes, that's definitely going to be a key piece of the readout, though like you said, the duration remains fairly short. Noah, anything else you'd like to add about safety?

Noah Berkowitz executive
#30

Okay. So, in general, the trial involving Parkinson's disease patients that we are going to present involves 28 days of therapy for those individuals. We ought to retain that. Thus, we are carrying out routine monitoring of patients to confirm safety and confirm that nothing problematic shows up. I won't be giving the data during this call, but that is a topic to review at the conference. I believe it's key to acknowledge that there is on-target activity that has been detected in patients' lungs, which needs to be followed. That is the reason anybody working in this area will perform things such as LFTs — pardon me, PFTs, pulmonary function tests — and that might be followed by high-resolution CT scans of the lung if anything looks concerning; and ultimately the aim will be to show that you have the proper benefit-risk profile for a drug. And we expect that should be acceptable. The — I will mention that it is so routine that there exists something known as the LIGHT initiative, which is guidance from experts that anybody handling LRRK2 targeting agents ought to be considering pulmonary function monitoring. So that is something we have built into our trial, and we will give updates at a suitable meeting.

Analyst analyst
#31

Understood. And related to that, when it comes to picking a dose, do you believe that translates straight across from Parkinson's to PSP?

Noah Berkowitz executive
#32

So, in our view, the two are closely connected. Consider this: what these conditions have in common is that each involves a toxic gain of function mutation tied to the illness or to how severe it is, correct? And we have an understanding of how a pathway gets activated for — namely the endolysosomal trafficking pathway, where LRRK2 occupies a central position. Therefore, our aim, as mentioned before, is to break down LRRK2 — down to at least 50%; we're aware that this is attainable in both conditions; we have grounds to think that this can produce a direct benefit. On various earlier calls or in publications, we've reported that we've carried out seeding experiments in PSP demonstrating that degrading LRRK2 can disrupt the spread of 4R tau polymerization. And on the whole, we're tackling a disease in which LRRK2 undoubtedly holds a central role. The pathological tau species that is nearly pathognomonic for the disease is 4R tau, correct? What I mean is, it turns up in every PSP patient at autopsy. And we know we ought to be capable of degrading this tau and stopping it from building up.

Daniel Bronder analyst
#33

Daniel Bronder here, filling in for Li. We wanted to ask whether you might provide some additional detail regarding the ARV-393 results you intend to present during this year's second half. You've previously mentioned there is early evidence of efficacy. What makes you confident about your data and about the molecule itself, such that it is worth continuing to develop? Also, what sort of data, and what kind of endpoint, ought we to anticipate in your presentation?

Randy Teel executive
#34

Sure, I'll have Noah weigh in, though you're correct to point out once more that toward the end of last year, we reported that even at doses lower than those we would have anticipated yielding an efficacious exposure range, we nonetheless observed some responses among patients with B or T-cell lymphomas, and we had seen favorable BCL6 degradation; however, regarding the data coming later this year, Noah?

Noah Berkowitz executive
#35

Yeah. I don't believe we'd be able to point specifically to those results, except to say that when you work in drug development, and you've got a novel mechanism of action, and you observe a drug capable of delivering a complete metabolic response in patients who otherwise face a fatal illness, you stay highly dedicated and excited about what lies ahead for that product.

Kripa Devarakonda analyst
#36

Anna here, filling in for Kripa. I've got a few things to ask. Moving over to the polyQ-AR degrader. Considering SBMA is, in a way, a disease that progresses and a market nobody has really tapped, I realize the program is still early, but I was curious whether there's anything you can — any direction you might offer regarding the strategy there? And is there anything that will be examined during this phase I that could in some way back up any early efficacy signals? And also, regarding 806, I'm wondering whether there are any early hints of interest in pancreatic, colorectal or lung cancer?

Randy Teel executive
#37

Yes, 027 comes first, Noah, Angela and then we'll return.

Noah Berkowitz executive
#38

Sure. Let me start near the end, and then I'll turn it over to Angela, because this is about clinical strategy—which means it's really early, so I can't get into that question in much detail. What I can do is lay out a range of possibilities, okay? We already know that in patients with SBMA, there's a pattern of muscle atrophy and fat infiltration that the right MRI sequencing can detect clearly. That gives you the basis for a surrogate marker for the disease. But establishing surrogacy calls for a lot of engagement with health authorities, plus a review of existing data and possibly new data, along with negotiation. We're just starting down this path, though, so it's something we might consider down the road. Past that, it's clear that in the absence of a surrogate approach, you'd turn to options such as the 6-minute walk test or some other functional gauge of how strong a patient is and whether they can avoid getting worse, correct? In the end, these individuals wind up confined to bed and start showing bulbar symptoms. That progression unfolds across a span of many years, yet it keeps moving forward and can be tracked. That's the approach, then. I'd say those are the kinds of possibilities within that range we're reviewing. Now I'll hand things over to Angela.

Angela Cacace executive
#39

All right. So when it comes to preclinical work, what this program is aiming at is getting rid of the underlying driver of spinal and bulbar muscular atrophy — that being the androgen receptor with the expanded polyglutamine repeat found in muscle. With ARV-027, we've managed to accomplish exactly that, and in the preclinical models we observe a really strong decrease within muscle, which then produces lessening of muscle atrophy. Grip strength goes up. Endurance gets better, and every one of those effects contributes to better muscle energetics, and we're able to quantify these via muscle biopsy, correct? So the aim of the preclinical effort, as it transitions into a translational one, is to quantify the decreases we observe in our healthy volunteers, and after that, in the Phase I trial, to also enroll SBMA patients and assess muscle biopsy for AR reduction and then polyQ-AR reduction. And after that, as Noah mentioned, to connect that with measures of muscle atrophy, which can subsequently be captured through muscle integrity measures — that means muscle MRI, so fat infiltration, muscle fat volume, things such as muscle volume, et cetera — and then function. So...

Randy Teel executive
#40

So perhaps I'll go back one additional click prior to returning to the KRAS question. However, only to remind everyone, this marks the third AR degrader that we've placed into the clinic; bavdegalutamide was therefore our initial one from several years back, among the earliest — the first PROTAC that we brought into the clinic, and it showed some strong efficacy signals plus decent tolerability at an early stage. Our subsequent AR degrader was 766, which we licensed out to Novartis roughly 2 years back for more than $1 billion combining upfront payments and milestones. So I simply want that to be understood clearly. AR is a field in which our expertise runs deep and we'll leverage it; now returning to your — the second question, regarding KRAS. Would you mind reminding me what that question was? My recollection is it concerned a move into PDAC, but please tell me what the question was.

Analyst analyst
#41

Yeah, do you have any early signs when it comes to PDAC colorectal compared to lung?

Randy Teel executive
#42

What kind of signs are you referring to? Are you asking about the direction of development?

Analyst analyst
#43

Do we have any initial signals of interest?

Noah Berkowitz executive
#44

Regarding the clinical trial, my sense is that we won't disclose the program's location, though I can say it has progressed more quickly than we anticipated, something I believe was just noted during this call. On top of that, we have already made a submission for a conference. So we'll observe how things unfold.

Randy Teel executive
#45

There's a lot of interest in this today...

Blake Gitler analyst
#46

Blake here, filling in for Jit. You touched on this a bit earlier, but what's your view on how the pan-KRAS program fits alongside 806? More specifically, is pan-KRAS meant to address variants other than G12D, or might it, with a clean therapeutic window, ultimately take the place of 806 altogether?

Randy Teel executive
#47

Yeah, that's a fair question, isn't it? G12D goes after G12D in a very targeted way, while pan-KRAS is meant to hit every mutant, no question; as for how the two can sit together, perhaps I'll offer a big-picture thought and then hand it over to Noah. Broadly speaking, though, we've viewed these as separate programs, correct? One could certainly argue that a G12D-specific degrader might have a profile more conducive to combining with other therapies. That's theoretical, of course. A pan-KRAS degrader with an excellent tolerability profile might also combine quite well. So we've treated them as separate programs. Noah, is there anything more you'd like to say about how they might progress?

Noah Berkowitz executive
#48

Right, and I believe that's really where the crux lies. As we've pointed out previously, one of the primary ways a degrader sets itself apart from an inhibitor is that it can keep degrading even when amplification or over-expression is present. That's something a pan-KRAS degrader would be well positioned to bring to the table. As you're aware, roughly 35% to 40% of pancreatic cancer patients carry G12D, which means the remaining 55% or 50% of patients have different variants. So within pancreatic cancer by itself, a pan-KRAS approach has a bigger opportunity than a G12D one. On differentiation, we're drawn to the possibility of combining them, and we're drawn to being able to genuinely get past resistance pathways — that's the idea. That same trend, though with lower percentages, holds true in non-small cell lung cancer, in colorectal cancer, and in other — possibly other GI tumors too.

Terence Flynn analyst
#49

Randy, you spent quite a bit of time discussing what this year could bring in the way of data from numerous early-stage programs. What's your thinking on possible partnerships for those programs? From what I understand, some you've held onto historically while others you've brought partners in on; so when you look at each one, how do you weigh partnering against keeping the rights?

Randy Teel executive
#50

Yeah, that's a wonderful question, Terence. Appreciate it; and maybe pulling back a level, alright? What we have built is a platform plus a team that has turned out several truly high-caliber clinical candidates that in our view could stand apart from the competition. We have — I nearly said 3 that are in the clinic, but per this morning's announcement, that figure is now 4 very recently, with 027 having gone in and 6723 for HPK1 set to enter the clinic later in the year. So that makes five, correct? For a small biotech, that's a great deal to handle. And because of that — that's what's driving the strategy to evolve away from only talking up the wonderful platform we possess, toward also recognizing that every program needs to be valued on its own and set apart from what it's competing against; and my sense is that as we advance those programs through this year and past it, not necessarily during this year, right, but as time goes on, we could get to points where we conclude it's wise for us to put resources behind certain programs and wise for somebody else to do so with others. You brought up our track record, right? Back in 2021 we struck a deal with Pfizer for Vep. I also referenced the luxdegalutamide arrangement with Novartis from 2024. And so that — so partnering has definitely formed a key piece of how we've operated previously and will continue to in the years ahead. When it comes to individual programs, we do our best to keep pharma companies informed about how our pipeline is progressing so that, should the moment arrive when we want to find a partner, we already have a sense of who that could be. So I'll likely hold back any further specifics until later, but figuring out the best way to carry each program forward is definitely something we're considering.

Paul Choi analyst
#51

Daniel here, filling in for Paul. We have a couple of questions about the spinal bulbar muscular dystrophy program. Could you give us guidance regarding the anticipated timing of the next data cut that's planned? Also, what kind of results might we see from the healthy volunteer study that would help lower the risk for the program, and would that include a muscle biopsy to measure intracellular AR concentrations?

Randy Teel executive
#52

Sure. Let me handle the first one since it's simple, then I'll hand it over to the team for the second; regarding timing, we've stated that we've only just begun in the clinic right now. So it's a little early to give guidance on when the first data will appear, so I wouldn't expect that anytime soon. But once that study is up and running, we'll aim to offer some direction on it; we've discussed somewhat the data emerging from 027, but Noah, please chime in about what we can present from the healthy volunteers.

Noah Berkowitz executive
#53

This is a standard study in healthy volunteers, though it includes a portion that ultimately follows up with some SBMA patients. So picture it as first determining the dose range — correct — through dose escalation, a single ascending dose phase in patients, which then leads into multiple ascending dose cohorts. We'll be examining PK, and there's a very robust PD element here that most of our other studies lack. What the PD involves is going after AR degradation in muscle, and those muscles can be biopsied, and we will do so. That's going to help us settle on the appropriate dose range for advancing into later trials. We aren't yet guiding you to — and incidentally, this applies both to the healthy volunteers in the SAD and MAD, but then in something like this confirmatory small cohort of SBMA patients at the end, we'll be performing those biopsies as well. We just — I don't believe we can guide you at this moment on when those results will come, but we — given that we only recently dosed our first patients, we'll keep you updated.

Michael Schmidt analyst
#54

Sarah here, filling in for Michael. I'd like to return to the pan-KRAS degrader. You've discussed the preclinical data you've observed at length, but I wanted to ask when you expect it to be IND-ready. Also, what's your present take on the opportunity in pan-KRAS, since I believe we've lately seen the first clinical data from a different pan-KRAS agent?

Randy Teel executive
#55

Right; the precise timing for the clinic for pan-KRAS hasn't been discussed by us yet. So I won't provide that guidance just yet. Even so, as you're able to see, we keep presenting data at various conferences. So things are progressing nicely. Regarding the opportunity for pan-KRAS, you're correct that other programs exist in this space, no doubt. Returning to those questions from — particularly from John at the beginning, it's an area where differentiation will definitely be necessary for us; yet we believe that space is one where having multiple programs across G12D and pan will prove helpful. Combinations involving those and other agents are going to matter as we go forward. Noah, is there anything else you'd like to add?

Noah Berkowitz executive
#56

I think we've said what we can on the pan-KRAS opportunity for now.

Sudan Loganathan analyst
#57

To begin with, I'd like to congratulate Randy on staying with Arvinas in his new position. I'm eager to collaborate with you and the group as Arvinas undertakes this abundance of thrilling new initiatives. My initial inquiry is this: as you get ready to launch the Phase Ib in PSP, which particular regulatory input are you requesting from the agency? On a different note, could regulatory input regarding PSP pose any danger of changing the development plan or schedules for the PD program? Last of all, could you describe your thinking on how the trial design will evolve for both PSP and PD endpoints, the enrichment approach, the length, and what would count as a registrational credibility data set for each indication?

Randy Teel executive
#58

Correct. All right. I appreciate the several questions, and I appreciate the remarks. See, to get the Phase Ib underway, it's the fairly standard process of steering it through the regulatory bodies. Given our guidance of beginning that during the first half of the year, you may assume we're proceeding there and everything is on schedule. Regarding data for PD versus PSP, Noah, I'll have you address that point about how development might impact each program.

Noah Berkowitz executive
#59

Okay, regarding that — there were a couple of questions there, correct? How might regulatory feedback affect both programs? And then there were also questions about enrichment strategy and similar topics. So there's no — we're simply submitting the IND, correct? So despite completing all of this work outside the U.S., we haven't had any interaction with the FDA. Therefore there's an opportunity here; and I believe it's more of an opportunity rather than a risk, right, to discuss these plans with the FDA. Think of our IND as a roadmap for the initial study we plan to run in our development program and as the start of a conversation, because the FDA already understands PSP and PD quite well, and we're hoping for very useful input. Drugs created for PSP and for Parkinson's disease carry different risk-benefit profiles. That's why PSP will be where we start. Eventually, though, we intend to hold a discussion regarding Parkinson's disease too. On this call, I'd rather not dive into the details of our Parkinson's development plan, since our guidance so far only addresses what we're currently doing in PSP. That said, once we wrap up those PSP discussions, the plan would then be to begin talks regarding Parkinson's disease. You asked what an enrichment strategy might involve. In PSP, it won't involve a biomarker or biomarker-based enrichment; instead, the emphasis will be on patients. Our trial enrollment will center on individuals with PSPRS — that is, those dealing with the more aggressive, symptom-heavy version of the illness. I can't recall the precise figure, though my sense is roughly 40% of PSP patients fall into that category. From there, we intend to build out an approach, and ultimately that approach will show us the path toward including a wider group of patients — or whether broadening things is even needed. When it comes to Parkinson's disease, here's what people can begin to expect: we're putting substantial effort into figuring out which biomarkers can forecast how the disease will progress. To do that, we're drawing on established resources that received significant funding and have generated plenty of published research — for example, PPMI, which is the Parkinson's Progression Initiative funded by the Michael J. Fox Foundation. We're leveraging that resource to assist in pinpointing markers. Consider it this way — we're now in a position to connect those findings with the biomarker shifts observed in our healthy volunteer study, as well as those we're seeing in our Parkinson's disease study. Our position is really distinctive competitively, since we're the sole company advancing a degrader in this area, and we've already shown — at minimum in healthy volunteers — that biomarker changes occur, which lets us begin linking those biomarkers to how Parkinson's disease progresses. Picture this as us pushing forward into doing that work with Parkinson's patients. Later on, that might unlock particular approaches for selecting patients, or enable certain analyses inside our trials. Other than that, there's nothing more I can share with you, even though it does suggest where we may be heading.

Etzer Darout analyst
#60

8 Luke here, filling in for Etzer. Regarding 102 and PSP — because PSP, you know, lacks any therapies that actually modify the disease, the entire focus has to be on symptom treatment. So what sorts of clinical endpoints, including early ones, will you be watching for? And what do regulators want to see in order to genuinely back that step into a registrational trial later this year? Then for vepdeg, I suppose, thinking about the worst case, if no collaboration is in place by the time of the PDUFA, is there a fallback plan for commercialization?

Randy Teel executive
#61

Perhaps I'll handle the second question about Vep, then hand things over to Noah for PSP. Look, like I mentioned, we're making solid progress on the partnership together with our colleagues at Pfizer. And should that turn into a problem, obviously, we're in a strong position with Pfizer to tackle that matter. As things keep advancing, it's becoming less worrisome, though of course, it remains something we're monitoring in case it's needed. Noah, over to you for the PSP questions.

Noah Berkowitz executive
#62

Right. In PSP, the PSP rating scale is what I'd call the gold standard, and there have been efforts to create drugs that modify symptoms — though not necessarily ones that modify the disease itself. So our plan is to use that scale in our regulatory — pardon me, our submission quality study later on. Clearly it will be part of the Phase Ib, and that trial won't have the power to fully assess it, but you can look for — it can still spot trends connecting what the biomarkers are doing with that instrument. There's another element we build into every study we run in these neurodegenerative conditions. We did this in our Parkinson's disease work, and we'll carry out comparable work in the PSP studies; even the Phase Ib examines things such as eye movements or other kinds of indicators or proxies for function, correct? This field is changing quickly, and certain markers of eye movement or of muscle movement might predict clinical outcomes; as of now they aren't recognized as registration quality tools, but we're folding them into our studies since we believe they might prove quite illuminating.

Randy Teel executive
#63

Much appreciated, operator, and I want to thank everyone joining us for those solid questions. To wrap things up, I'd just note that with our identity now settled as a Phase I organization, what matters most is plainly advancing the studies, generating strong results, and getting the choices right. So as we proceed along those lines during the months ahead, we're eager to keep everyone informed. Many thanks to each of you for being on this call.

Operator operator
#64

That concludes today's call. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Arvinas, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Arvinas, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.